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Phase II Randomized Study of Two Regimens of
Sequentially Administered Mitomycin C and Irinotecan in
Patients with Unresectable Esophageal and
Gastroesophageal Adenocarcinoma
Maryam B. Lustberg, MD,* Tanios Bekaii-Saab, MD,* Donn Young, PhD,† Gregory Otterson, MD,*
William Burak, MD,‡ Abbas Abbas, MD,‡ Barbara McCracken-Bussa, BA,*
Mark E. Lustberg, MD, PhD,* and Miguel A. Villalona-Calero, MD*§
Background: Based on the observation of topoisomerase-1, upregu-
lation by mitomycin C (MMC), and the phase I antitumor activity of
sequential MMC/irinotecan in esophageal cancer, we conducted a
phase II evaluation of two schedules of this combination in previ-
ously untreated stage III/IV esophageal/gastroesophageal junction
adenocarcinomas.
Patients and Methods: Patients (n 76) were randomized to either
6 mg/m2 MMC on day 1 and 125 mg/m2 irinotecan on days 2 and
9 (arm A) or 3 mg/m2 MMC on days 1 and 8 and 125 mg/m2
irinotecan on days 2 and 9 (arm B). Each cycle was repeated every
28 days. Restaging was planned after two cycles, and resections
were performed whenever possible. A two-stage Simon minimax
design was used for each arm, with a “pick-the-winner” approach
based on efficacy.
Results: The response rate (complete response  partial re-
sponse) in 73 evaluable patients was 52% (21 of 40 patients) for
arm A and 33% (11/33) for arm B. Moderate or severe toxicity
was similar. Twenty-seven patients were resected (20:7, arm
A:B). There was one complete pathologic response; five others
were node negative.
Conclusion: Irinotecan/MMC is feasible in esophageal/gastro-
esophageal junction adenocarcinoma. MMC (6 mg/m2) every 28
days for up to six cycles is the recommended modulatory dose for
irinotecan in future trials.
Key Words: Gastroesophageal adenocarcinoma, Irinotecan, Mito-
mycin C, Topoisomerase I.
(J Thorac Oncol. 2010;5: 713–718)
Irinotecan has antitumor activity in many malignancies.Because topoisomerase I (Topo I) is the cellular target of
irinotecan, its cellular level and activity may be proportional
to the cytotoxic effects of irinotecan.1,2 Solid tumors have
increased Topo I when compared with corresponding non-
malignant tissue, and increased Topo I activity corresponds to
increased sensitivity to Topo I interactive agents.3,4
The mechanisms of tumor resistance to irinotecan5
include mutations of the Topo I gene and stable decrements
in Topo I activity.6,7 The exposure to irinotecan produces
a rapid, transient decrease in Topo I concentration, which
in cell cultures correlates with a decrease in irinotecan
cytotoxicity.6,7
Because the increases in Topo I activity were re-
ported in vitro after treatment with mitomycin C (MMC)
with synergistic irinotecan cytoxicity,8 we previously con-
ducted a phase I clinical trial evaluating MMC as a
modulating agent at doses of 6 mg/m2 24 hours before
irinotecan.9 Patients received MMC every 4 weeks with a
cumulative dose-cap of 36 mg/m2. At these doses, we not
only showed an acceptable toxicity profile at full doses of
irinotecan and lack of pharmacokinetic interactions but
also substantial antitumor activity in patients with treat-
ment refractory malignancies, including esophageal and
gastric cancers. An induction of Topo I expression in
mononuclear cells was associated with response to the
regimen.9
Because we previously demonstrated the upregulation
of Topo I by MMC, we designed a randomized phase II
clinical trial in patients with previously untreated advanced
esophageal and gastroesophageal junction (GE) adenocarci-
nomas. To discern whether MMC at the modulatory dose (6
mg/m2 24 hours before irinotecan) has an effect on clinical
activity or toxicity, patients were randomized to two dose
schedules of MMC in combination with irinotecan, with the
goal of selecting one of two schedules for further efficacy
evaluation studies using a 2-stage pick the winner approach.
The two dose schedules compared modulatory dose versus
nonmodulatory dose of MMC, while keeping the total cumu-
lative monthly dose of both MMC and irinotecan the same.
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PATIENTS AND METHODS
Eligibility Criteria
Patients had histologically confirmed advanced esopha-
geal or GE adenocarcinoma and were not candidates for surgical
intervention at presentation, as assessed by a surgical oncologist.
Squamous histology was excluded. Eligibility included (a) age
18 years, no pregnancy, or lactation; (b) Eastern Cooperative
Oncology Group performance status of 2; (c) life expectancy
12 weeks; (d) no previous chemotherapy; (e) prior radiation
was allowed if20% of the bone marrow was irradiated and the
target lesions were not in the radiation field; (f) no major
surgeries within 28 days; (h) adequate organ function including
absolute neutrophil count 1500/mm3, hemoglobin 9 g/dl,
platelet count 100,000/mm3, serum creatinine 1.5 mg/dl or
creatinine clearance 60 ml/min, serum bilirubin 1.5 mg/dl,
transaminases 3 times upper normal limit; (i) no active neo-
plastic involvement of the nervous system; (j) no uncontrolled
diabetes mellitus; (k) no history of myocardial infarction within
6 months, congestive heart failure requiring therapy, and unsta-
ble angina; (l) no coumadin treatment; (m) no coexisting med-
ical or psychiatric disorders interfering with consent or follow-
up; (n) quantifiable disease by either computed tomography
(CT) or positron emission tomography (PET) was required. All
patients provided informed consent.
Treatment Plan
A cycle consisted of 28 days. The MMC dose was
either 6 mg/m2 (arm A) on day 1 or 3 mg/m2 on days 1 and
8 (arm B). The MMC dose was limited to a total of 36 mg/m2
(six cycles) and 125 mg/m2 irinotecan on days 2 and 9 (24
hours after MMC, when the MMC was required). Two weeks
of rest completed the cycle. Ondansetron or granisetron and
dexamethasone premedication were used. Loperamide was
recommended at the earliest onset of diarrhea. Prophylactic
use of colony-stimulating factors was not permitted. Use of
erythropoietin for hemoglobin 10 g/dl was permitted.
Dose Modifications
Weekly cell counts, chemistries, and electrolytes were
obtained. Within a cycle, doses were held for neutropenic
fever and grade 3/4 hematologic and nonhematologic toxic-
ities. For subsequent cycles, MMC was reduced by 25% for
grade 4 hematologic toxicity, neutropenic fever, and grade
3/4 nonhematologic toxicities. Irinotecan was reduced by
25% for grade 4 nausea and grade 3 nonhematologic toxici-
ties, and 50% for grades 4 nonhematologic toxicities.
Clinical Benefit Evaluation
The measurement of tumor size or tumor metabolic
activity was performed before treatment and after every two
cycles. Patients had baseline CT measurements, and 2-fluoro-
2-deoxy-D glucose (FDG)-PET standard uptake values
(SUV) evaluations were obtained in patients with GE tumors
that were not measurable by CT at baseline. CT and PET
responses were assessed based on RECIST 1.0 criteria10 and
European Organization for Research and Treatment of Can-
cer (EORTC) criteria,11 respectively. The latter defines com-
plete metabolic response as complete resolution of SUV
within the tumor volume and progressive metabolic disease
as an increase in SUV of 25% in target lesions or the
appearance of new lesions. Partial metabolic response is an SUV
reduction of25% in target lesions after two cycles, and stable
metabolic disease is an increase or decrease of 25%. Surgical
resections were offered to patients who were suitable surgical
candidates. Resected patients were referred for chemotherapy
and radiation when appropriate. Criteria for study removal in-
cluded documented or symptomatic disease progression, unac-
ceptable toxicity that did not respond to dosage modifications,
pregnancy, withdrawal of consent, treatment delay of3 weeks,
dose reduction of irinotecan to 25 mg/m2, hemolytic uremic
syndrome, or evidence of pulmonary interstitial fibrosis.
Statistical Considerations
The primary objective was to select one of two regi-
mens based on objective responses for evaluation in future
efficacy trials. Patients were randomized using a stratified
fixed block design, with stratification by locally advanced or
metastatic disease. Each arm was treated as a parallel phase II
study with an open-label, minimax two-stage design.12 The
primary endpoint was objective response using RECIST or PET
EORTC response criteria. Either regimen was considered inef-
fective if the true response probability was 30% (p0), because
response rates in previously reported phase II trials of single
agent irinotecan in stomach cancer approached this level. A
regimen was worthy of further study if the true response prob-
ability was 50% (p1). A two-stage design of 28 and 39
patients, with an alpha error of 0.10 and beta error of 0.10 was
obtained. If 7 patients demonstrated responses in the first 28
evaluable patients, the regimen was terminated early and
deemed ineffective. If8 patients showed responses in the first
28 patients, 11 additional patients were treated for a total of 39.
If15 of the 39 patients showed responses, the regimen was not
recommended for further study.
RESULTS
Patient Population
Between July 2002 and May 2006, 82 patients were
consented. Among them 77 were treated (Table 1). The
reasons for no treatment included consent withdrawal before
treatment, screening eligibility failure (one in each), and three
patients with declining performance status or rapidly progres-
sive disease (PD) to whom treatment was not offered. Forty-
three patients had lower esophageal and 33 GE adenocarci-
nomas; one patient had fundus stomach cancer. The distribution
of stages at baseline was 24 stage III, 24 stage IV-A, and 29
stage IV-B. CT scan was completed for baseline staging in all
patients, whereas baseline PET was obtained in 50 patients
(65%) and endoscopic ultrasound in 11 patients (14%).
The Data Safety Monitoring Board recommended stop-
ping enrollment to arm B when it became clear that the
prespecified response rate would not be met. Patients con-
sented, but not treated, before halting arm B were allowed
treatment on arm A. Overall, 42 patients received treatment
on arm A and 35 on arm B. One patient on arm B was later
determined to be ineligible because of lack of quantifiable
disease by CT or PET.
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Treatment Summary
The distribution of the number of cycles was as fol-
lows: 10 one cycle, 47 two cycles, 5 three cycles, 6 four
cycles, 3 five cycles, and 5 six cycles. There were no
significant differences in the number of cycles by treatment
group. The reasons for discontinuing treatment after one
cycle included PD (three patients), toxicity (four patients),
death (two patients), and one early surgery. The reasons for
discontinuation after two cycles included surgery (22 pa-
tients), tumor progression (17 patients), referral for concur-
rent chemotherapy and radiation (5 patients), or radiation (2
patients), and toxicity (1 patient).
Toxicity
Cumulative incidence of toxicities was similar for both
arms (Table 2). A total of 22 patients (52%) in arm A and 16
patients (47%) in arm B needed dose reductions. Six patients in
arm A and five patients in arm B needed reductions for both
drugs. There was no evidence of chronic myelosuppression,
hemolytic uremic syndrome, or pulmonary interstitial fibrosis.
Six patients died because of reasons other than tumor progres-
sion. The reasons for fatality included: thrombosis in two pa-
tients, sudden cardiac arrest of unknown etiology in two patients,
and neutropenic sepsis in one patient. One patient was transi-
tioned to hospice after complications of gastrointestinal bleed-
ing. There were no cases of intraoperative mortality.
Efficacy
Antitumor activity is depicted in Table 3. Of the 76
eligible patients receiving at least one cycle of the combination
treatment, 70 patients (92%) had repeat tumor measurements
after two cycles. Three patients died before repeat imaging and
were assigned as PD. Two patients were considered response
nonevaluable because of removal from the study after one cycle
because of toxicity without progression. An additional patient
was considered to be nonevaluable as he withdrew consent and
went to surgery after the first dose of irinotecan.
Forty patients had baseline and follow-up PET imaging
to assess best overall response (complete response [CR] and
partial response), whereas 30 patients had response assess-
ment only by CT. Figures 1A, B depict waterfall plots of
changes in the tumor size and metabolic activity, respec-
tively. The best overall response rates were 52% (95% con-
fidence interval 36–68) for arm A and 33% (95% confidence
interval 18–52) for arm B (respectively, 50% and 33% by
intent-to-treat). Overall median progression free survival was
155 days for arm A and 95 days for arm B.
Twenty-eight patients (37%) were deemed surgical
candidates at reassessment, and 27 of them were successfully
resected (20 in arm A and 7 in arm B). One patient in arm B
went to surgery and was not resectable because of peritoneal
implants. The median number of cycles before surgery was 2
TABLE 1. Patient Characteristics
Arm A (n  42) Arm B (n  35a)
Age (yr), mean  SE 58.9  1.6 61.7  2.2
Gender, male:female 39:3 33:2
ECOG Score, N (%)
0 21 (50) 15 (43)
1 17 (40) 19 (54)
2 4 (10) 1 (3)
Stage, N (%)
III 17 (40) 7 (20)
IV-A 14 (33) 10 (29)
IV-B 11 (26) 18 (51)
Metastatic sites, N (%)
Lung 3 (7) 2 (6)
Liver 8 (19) 15 (43)
Bone 1 (2) 1 (3)
Lymph nodes 20 (48) 26 (75)
a One patient in arm B was ruled ineligible because of lack of quantifiable disease.
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Adverse Events
Arm A Arm B
Grade 3 Grade 4 Grade 3 Grade 4
Hematologic toxicity, n (%)
Leukopenia 3 (7) 4 (10) 4 (12) 1 (3)
Anemia 5 (12) 0 1 (3) 0
Thrombocytopenia 1 (2) 0 0 0
Neutropenia 3 (7) 6 (14) 3 (9) 5 (15)
Neutropenic fever 4 (10) 2 (5) 3 (9) 2 (6)
Nonhematologic toxicity, n (%)
Fatigue 2 (5) 0 5 (15) 0
Nausea/vomiting 7 (17) 3 (7) 6 (18) 0
Diarrhea 9 (21) 6 (14) 4 (12) 5 (15)
Dehydration 8 (19) 3 (7) 6 (18) 4 (12)
Sepsis 0 1 (2)a 0 0
Anorexia/weight loss 2 (5) 0 3 (9) 1 (3)
Thrombosis 0 3 (7)b 1 (3) 1 (3)
Cardiac 1 (2) 1 (2)c 0 1 (3)c
Acute renal failure 5 (12) 0 0 1 (3)
Bleeding 0 1 (2)a 0 0
a Includes one patient each with grade 5 toxicity.
b Includes two patients with grade 5 toxicity.
c Includes one patient with sudden death in each arm.
TABLE 3. Antitumor Activitya
Arm A, n (%) Arm B, n (%)
Overall response rates (n  76)b
CR 2/40 (5) 1/33 (3)
PR 19/40 (47)c 10/33 (30)c
SD 12/40 (30) 9/33 (27)
PD 7/40 (18) 13/33 (39)
Not evaluable 2 1
a Antitumor activity assessed by PET EORTC criteria when available and by CT
RECIST criteria 1.0 when no PET was available.
b Six patients did not get repeat imaging: Three patients (one in Arm A and two in
Arm B) died before repeat imaging and were assigned as PD. One patient in Arm A
went to surgery during cycle 1, and one patient was taken off trial for toxicity without
progression. In Arm B, one patient was removed for toxicity without progression.
c 95% confidence interval for overall response (CR  PR) 36–68% and 18–52%
for Arm A and B, respectively.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; PET, positron emission tomography; EORTC, European Organization for
Research and Treatment of Cancer.
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(range 1–6). Pathologic staging in these patients is depicted
in Table 4. One patient (arm A) had a complete pathologic
response. Five other patients had node negative disease.
Among the patients with PET CR, two went to surgery and
both had pathologic stage T3N1. The other was not a surgical
candidate because of medical comorbidities. Fifteen patients
were referred for chemoradiation, and two patients were
referred for radiation alone.
DISCUSSION
On the basis of preclinical rationale that upregulation of
Topo I by MMC would increase the antitumor activity of
irinotecan, and demonstration of encouraging antitumor ac-
tivity in refractory esophageal/gastric cancer patients in a
phase I trial,9 we conducted this phase II trial in advanced
esophageal and GE adenocarcinoma patients. The activity of
modulatory doses of MMC in combination with standard
doses of irinotecan in two schedules was evaluated. The
randomized nature of the study permitted selection of the
most suitable schedule for future trials.
The incidence of esophageal cancer is increasing in the
United States and Europe with most of the increase because
of adenocarcinomas, which now accounts for more than half
of newly diagnosed cases.13 Surgical resection is the optimal
treatment option but the majority of patients are not candi-
dates for resection at the time of presentation because of
FIGURE 1. A, Plot of percentage
change in computed tomography
(CT) tumor size by arm. Individual
percentage change in tumor size by
CT scan according to the treatment
arm (n  30). B, Plot of percentage
change in standard uptake values
(SUV) by arm. Individual percentage
change in tumor SUV by positron
emission tomography according to
the treatment arm (n  38). Two
additional patients with progressive
disease because of new metabolic
lesions were not included.
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locally advanced or metastatic disease. Neoadjuvant chemo-
therapy and radiation have been investigated to increase the
number of patients amenable to resection and ultimately
improve overall survival.
The combination of cisplatin (Cis) and 5-fluoruracil
(5-FU) has been the most commonly investigated neoadju-
vant regimen with variable results across trials. The North
American Intergroup Trial failed to see a survival advantage
in the preoperative group with Cis/5-FU.14 In the Medical
Research Counsel trial, however, the chemotherapy-treated
group had improved survival and increased R0 resections.15
The differences in outcomes have been attributed to larger
sample size and higher proportion of adenocarcinomas in the
Medical Research Counsel trial compared with the Intergroup
trial. Additional trials have shown promising results with
Cis/5-FU16 and with epirubicin combined with Cis/5Fu.17
The rates of pathologic CR remain low with existing
neoadjuvant chemotherapy regimens. The combination of
radiation with Cis/5-FU-based chemotherapy has proven sur-
vival advantage to radiation therapy alone in unresectable
disease.18 When preoperative chemoradiation is compared
with surgery alone, improved local control is reported but
improvements in survival have not been consistently demon-
strated.19–21 Investigation of additional systemic strategies is
clearly needed. To that regard, Radiation Therapy Oncology
Group (RTOG) 0113 explored 2 taxane-containing regimens
followed by conventional chemoradiation.22 However, both
regimens failed to meet the prospectively set 1-year median
survival endpoint.
In this study, patients with previously untreated ad-
vanced esophageal and GE-junction adenocarcinomas were
randomized to two schedules of the combination of MMC
and irinotecan. Although caution must be exercised to not
perform inferential statistical comparisons in a randomized
phase II trial,23 toxicities were similar between the two arms,
and only arm A met the prespecified response criteria
(50%). Treatment did not interfere with resection and
possibly increased the number of resectable patients. In
contrast to many neoadjuvant trials, patients were ineligible
for resection before therapy. Of the 28 patients taken to
surgery, 19 (68%) were down staged, including all patients
with stage IVa disease. One patient had a complete patho-
logic response. Patients who had node positive disease at
surgery were referred for chemotherapy and radiation.
The toxicity of the combination regimen of MMC and
irinotecan is comparable with other neoadjuvant regimens.
The most common 3 toxicities reported in the Intergroup
trial with Cis/5-FU were neutropenia (29%) and mucositis
(25%).14 Similarly, in the Medical Research Council Adju-
vant Gastric Infusional Chemotherapy (MAGIC) trial, 3
neutropenia occurred in 24% of patients.17
We can only speculate why one schedule (arm A)
performed better than the other (arm B). The randomization
prevented investigators’ bias in patient selection as a factor,
FIGURE 2. A, Kaplan-Meier plots of progression free survival by percentage change in standard uptake values (SUV). Kaplan-
Meier plots showing progression-free survival according to percent decreases in SUV 25% and 25%. There is a statistically
significant difference between patients with and without a metabolic response (P  0.02). B, Kaplan-Meier plots of overall sur-
vival by percentage change in SUV. Kaplan-Meier plots showing overall survival according to percent decreases in SUV 25%
and 25%. There is a statistically significant difference between patients with and without a metabolic response (P  0.006).
TABLE 4. Pathologic Responsesa
Arm A Arm B
Total N 20 8
Complete pathologic response—T0N0 1 (5) 0
Stage I—T1N0 2 (10) 0
Stage IIA
T2N0 0 2 (25)
T3N0 1 (5) 0
Stage IIB
T1N1 1 (5) 0
T2N1 4 (20) 0
Stage III
T3N1 11 (55) 5 (62)
Stage IV 0 1 (13)
a Surgical approach: thoracotomy, 13 patients; nonthoracotomy, 14 patients. The
median number of nodes resected was 12. One patient was unresectable.
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but an imbalance occurred between the arms in terms of stage
IVB disease. This imbalance could account for differences in
survival and even progression-free survival, but less so for
antitumor response after two cycles. It is possible that MMC
may have independent antitumor activity, instead of modu-
latory activity. However, a dose-dependent effect for a single-
agent treatment would be expected to be higher than 3 mg/m2,
as the total dose per cycle was the same.
A significant challenge in GE tumors is the ability to
assess response in locally advanced disease. The assessment of
metabolic activity by PET has been increasingly used by sur-
geons and medical oncologists. This study was specifically
designed to use PET scans for response assessments in those
patient whose tumors could not be measured by CT scan alone,
expanding patient eligibility for response evaluation. The arbi-
trary cutoff of 25% change in metabolic activity to define
response or progression was chosen based on the EORTC
criteria although other cutoff values have been used in other
studies.11 As shown by others,24,25 FDG PET was a reasonable
tool for assessment of response and respectability but did not
have complete correlation with surgical pathology. That is, the
two patients with complete metabolic responses had node positive
disease at the time of surgery. Both progression-free and overall
survival were associated with PET SUV changes (Figure 2).
To define this regimen’s role in esophageal/GE tumors,
combination with radiation or evaluation in a sequential
fashion with platinum based therapy and radiation will be
necessary. In fact, most patients with node positive disease at
surgery went on to receive Cis/5FU with radiation in the
adjuvant setting with good tolerability. It would be of interest
to see whether a greater local control can be achieved before
surgery with either strategy.
In conclusion, the results of this trial show that low
dose MMC in combination with irinotecan can be safely
given to patients with esophageal and GE adenocarcinomas.
Single dose of MMC was more efficacious than split dosing.
The antitumor activity observed encourages future clinical
trials using the recommended schedule of 6 mg/m2 MMC on
day 1 and irinotecan 125 mg/m2 on days 2 and 9, every 4
weeks. However, in the setting of locally advanced disease,
based on low number of complete pathologic responses, the
combination with radiation or a sequential use of this regimen
with Cis/5FU and radiation would be a more reasonable
schedule for future exploration of this regimen.
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